Orforglipron: The Oral Small-Molecule GLP-1 and Its 2025-2026 Trial Readouts

Most of the GLP-1 conversation over the past few years has centered on injectable peptides. Orforglipron is a different kind of molecule, and that distinction is the whole point. This research-log entry tracks what the 2025-2026 Phase 3 readouts actually showed, and what changed on the regulatory side.

What orforglipron is (and is not)

Orforglipron is Eli Lilly's oral, once-daily GLP-1 receptor agonist. Critically, it is not a peptide. It is a non-peptide small molecule that binds and activates the GLP-1 receptor, which is why our peptide library does not list it as an entry. That single structural fact drives most of its practical differences from the incretin drugs people already know.

Compare it to semaglutide, a peptide. Injectable semaglutide is dosed weekly under the skin. The oral peptide version (Rybelsus) exists, but because peptides are poorly absorbed by mouth, it relies on an absorption enhancer and must be taken on an empty stomach with a small sip of water, then followed by a 30-minute wait before food or other medication. Orforglipron, as a small molecule, sidesteps that pharmacokinetic problem: it is designed to be taken at any time of day, with or without food or water. No injection, and no meal-timing ritual — the two advantages it holds over both injectable peptides and peptide-based oral pills. Tirzepatide, a dual GIP/GLP-1 peptide, remains injection-only.

The ATTAIN program (obesity)

Orforglipron's obesity evidence comes from the Phase 3 ATTAIN program.

ATTAIN-1 enrolled 3,127 adults with obesity or overweight plus a weight-related condition, testing 6 mg, 12 mg, and 36 mg doses over 72 weeks. All three doses met the primary endpoint of superior weight reduction versus placebo, with the highest dose producing roughly 12% average body-weight loss (reported as about 27.3 lbs). Full results were published in The New England Journal of Medicine.

ATTAIN-2 studied adults who had both obesity/overweight and type 2 diabetes — a population that typically loses less weight on incretin therapy. On the top dose, participants lost an average of about 10.5% of body weight (roughly 22.9 lbs). Those results were published in The Lancet.

ATTAIN-MAINTAIN, reported in December 2025, looked at a newer question: whether an oral small molecule could hold weight loss that people had already achieved on injectable incretins. It evaluated orforglipron for weight maintenance over 52 weeks after switching off injectable GLP-1 therapy, and met its endpoints — an early signal for oral maintenance after injectable induction.

Across the obesity trials, the safety profile was described as consistent with the injectable GLP-1 class, with gastrointestinal effects (nausea and related symptoms) the most commonly reported adverse events.

The ACHIEVE program (type 2 diabetes)

The diabetes evidence sits in the Phase 3 ACHIEVE program, tested at 3 mg, 12 mg, and 36 mg.

ACHIEVE-2 compared orforglipron against dapagliflozin (an SGLT-2 inhibitor) in adults inadequately controlled on metformin. ACHIEVE-5 compared it against placebo in adults on titrated insulin glargine, with or without metformin and/or an SGLT-2 inhibitor. Both, reported in October 2025, met their primary and key secondary endpoints at 40 weeks — meaningful A1C reduction, weight loss, and improvements in several cardiovascular risk factors.

The most scrutinized readout was ACHIEVE-3, detailed in February 2026 — the first head-to-head Phase 3 trial pitting orforglipron against oral semaglitude (the peptide pill) in adults inadequately controlled on metformin. Orforglipron came out ahead across the primary and all key secondary endpoints, delivering greater A1C reduction and greater weight loss. Results were published in The Lancet. For context, this is a small molecule outperforming a peptide on the peptide's own oral turf.

Regulatory status

This is where the timeline moved fastest. Lilly submitted orforglipron for weight management to global regulators by the end of 2025. On April 1, 2026, the FDA approved it under the brand name Foundayo for chronic weight management in adults with obesity or overweight with weight-related conditions, alongside diet and physical activity. The approval was notable procedurally: it was the first new molecular entity cleared under the FDA's National Priority Voucher program, reportedly about 50 days after filing. The separate submission for the type 2 diabetes indication is planned for 2026 and, as of this writing, is not yet an approved use.

For how we categorize approval versus investigational status here, see our FDA status reference.

The research-log takeaway

Orforglipron matters less because of any single efficacy number and more because of what it demonstrates: a non-peptide small molecule can hit GLP-1-class weight and glycemic outcomes while removing the needle and the food-timing rules that constrain peptide orals. The head-to-head ACHIEVE-3 result and the fast obesity approval are the two data points worth watching as the diabetes filing plays out. As always, the trial names above (ATTAIN-1/2/MAINTAIN, ACHIEVE-2/3/5) are the anchors to check against primary sources.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.